Today we honor patients living with NET Cancer. Neuroendocrine tumor (NET) incidence is rising, but with greater awareness we can work to create better outcomes for patients. RayzeBio is proud to support patients living with NETs today and every day. ? #NETCancerDay #LetsTalkAboutNets
RayzeBio
生物技术研究
San Diego,CA 20,566 位关注者
Targeted innovative radiopharmaceuticals for cancer
关于我们
RayzeBio Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies through our differentiated radiopharmaceutical platform @Bristol Myers Squibb or www.bms.com
- 网站
-
https://www.rayzebio.com
RayzeBio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Diego,CA
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
US,CA,San Diego,92121
RayzeBio员工
动态
-
This week we celebrate #NuclearMedicineWeek and all the nuclear medicine professionals that are revolutionizing healthcare. Through diagnostics, theranostics, molecular imaging and innovative techniques, nuclear medicine professionals are changing patient care and treatment. At RayzeBio, we are grateful for your passion, dedication and commitment to advancing patient outcomes. #RPTs #radiopharmaceuticals #gratitdue?
-
At RayzeBio, a Bristol Myers Squibb Company, we are on a mission to become the global leader in radiopharmaceuticals. With a history rooted in biotech, now part of the best-in-class capabilities of Bristol Myers Squibb, we are harnessing the power of targeted radioisotopes to focus on improving survival of people living with cancer. ? We’re expanding our innovative and patient-focused team in San Diego and Indianapolis. View our open roles here: https://lnkd.in/gKwu3cn3
-
As of today, RayzeBio, Inc. is officially part of Bristol Myers Squibb! We are excited to continue our mission and look forward to delivering breakthrough therapies through our differentiated radiopharmaceutical platform as part of BMS. Follow our progress Bristol Myers Squibb
-
RayzeBio转发了
We are excited to announce our proposed acquisition by Bristol Myers Squibb. Our leading position in radiopharmaceutical therapeutics coupled with the broad and deep expertise of BMS in oncology allows us to work together to bring forth this next wave of innovation in cancer therapy for patients. https://lnkd.in/gTEy-mC4
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
businesswire.com
-
We are excited to announce our proposed acquisition by Bristol Myers Squibb. Our leading position in radiopharmaceutical therapeutics coupled with the broad and deep expertise of BMS in oncology allows us to work together to bring forth this next wave of innovation in cancer therapy for patients. https://lnkd.in/gTEy-mC4
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
businesswire.com